The agreement will allow diaDexus to obtain access to Agilent's customizable microarray technology for research into the molecular basis for cancer and other diseases...The milestones are related to acceptance by Taisho of a CART-activated version of a G protein-coupled receptor target selected by Taisho and a request by Taisho that Arena screen the receptor using Arena's in-house chemical library...The trials are designed to further demonstrate the drug's safety and efficacy in different clinical

4SC , of Martinsried, Germany, received a grant of EUR1.3 million (US$1.09 million) from the European Commission for discovery of novel treatment regimens for severe malaria

BMS will use the technology for generation of internal research knockout mice to gain predictive information about gene products. • Ligand Pharmaceuticals Inc., of San Diego, received marketing authorization from the European Commission for Panretin gel for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma

and motor function in 25 patients with chronic schizophrenia. • Epigenomics, of Berlin, said on behalf of the Human Epigenome Consortium that it received a grant for EUR1.2 million (US$1.02 million) from the European Commission to fund mapping of the DNA methylation patterns of the entire human genome. • Immunomedics Inc., of Morris Plains, N.J., moved to quell rumors concerning its cancer therapeutics program

The study focused on CML cell inhibition of NK cells and T cells. •Serono S.A., of Geneva, said the European Commission granted the company Orphan Medicinal Product designation for the recombinant human growth hormone product Serostim, the first such designation the EC has granted under its new regulation on orphan products passed in January. •Specialty Laboratories Inc., of Santa Monica, Calif., filed a registration statement with the SEC for an IPO

1) •Aventis Behring LLC, of King of Prussia, Pa., said the European Commission approved Helixate NexGen, a recombinant product for the treatment of hemophilia A. •Genometrix Inc., of The Woodlands, Texas, and Genomics Collaborative Inc., of Cambridge, Mass., are collaborating to analyze thousands of clinically characterized DNA samples for profiling single nucleotide polymorphisms

DP-b99 is designed to control apoptotic processes by regulating the intracellular homeostasis of divalent metal ions. • Elan Corp., of Dublin, Ireland, said the European Commission has granted the company marketing authorization for Myocet, the company's liposome-encapsulated doxorubicin citrate complex, in combination with cyclophosphamide for treatment of metastatic breast cancer

The company has traded on the OTC Bulletin Board under the symbol NTII since 1998, and will keep that symbol when listed on Nasdaq. • QLT Inc., of Vancouver, British Columbia, and Ciba Vision, the Atlanta-based eye care unit of Novartis AG, said the European Commission granted marketing authorization for Visudyne for the treatment of wet age-related macular degeneration

The European Commission will make the final decision in approximately three months...The Committee for Proprietary Medicinal Products recommended the European Commission approve the product for marketing in the 15 member states of the European Union

The patent has broad composition of matter and use claims for hairpin ribozymes and is licensed exclusively to Gene Shears. • Genzyme Transgenics Corp., of Framingham, Mass., and Genzyme General, of Cambridge, Mass., said the FDA granted orphan drug status for recombinant human antithrombin III (rhATIII) to treat ATIII-dependent heparin-resistant patients requiring anticoagulation. • Glaxo Wellcome plc, of London, and SmithKline Beecham plc, of London, said the European Commission approved the

The favorable opinion now has to be endorsed by the European Commission before Myocet, formerly called Evacet, receives final marketing authorization

The company received $4.8 million in 1999, when it identified several compounds that display antibacterial and antiviral activity. • Genzyme General, of Cambridge, Mass., and GelTex Pharmaceuticals Inc., of Waltham, Mass., said the European Commission granted marketing approval in Europe for Renagel capsules for the control of hyperphosphatemia in adult patients on hemodialysis

No financial terms were released. • Biopure Corp., of Cambridge, Mass., received marketing authorization for Oxyglobin (hemoglobin glutamer-200 bovine) from the European Commission for the treatment of canine anemia, a condition that threatens millions of dogs yearly

MedImmune Inc., of Gaithersburg, Md., and Abbott Laboratories, of Abbott Park, Ill., said the European Commission granted a marketing license for Synagis (palivizumab) for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus (RSV) in high-risk infants

BioChem Pharma Inc., of Laval, Quebec, received approval from the European Commission to market Zeffix (lamivudine), a treatment for hepatitis B, in all 15 European Union countries

TP20, the product name for sCR1sLex, targeted injured lung tissue, resulting in reductions in vascular permeability and inflammation. • BioChem Pharma Inc., of Laval, Quebec, said the European Union’s Committee for Proprietary Medicinal Products recommended approval of Zeffix, an oral treatment for chronic hepatitis B. The European Commission will make a final determination. • Cangene Corp., of Mississauga, Ontario, filed an investigational new drug application seeking permission to begin

The action serves as the basis for European Commission approval, which is typically issued in four months and would result in a single marketing authorization valid in all 15 European Union member states. • Coulter Pharmaceutical Inc

In its ruling, the court noted the European Commission's approval of Biogen's dosage, and said that approval "makes it likely to a large degree that the specified dosage is sufficient and not an under-dosage

Expected next is the issuance of a marketing authorization by the European Commission